Literature DB >> 26630263

Targeting ubiquitination for cancer therapies.

John Kenneth Morrow1,2, Hui-Kuan Lin3, Shao-Cong Sun4, Shuxing Zhang1.   

Abstract

Ubiquitination, the structured degradation and turnover of cellular proteins, is regulated by the ubiquitin-proteasome system (UPS). Most proteins that are critical for cellular regulations and functions are targets of the process. Ubiquitination is comprised of a sequence of three enzymatic steps, and aberrations in the pathway can lead to tumor development and progression as observed in many cancer types. Recent evidence indicates that targeting the UPS is effective for certain cancer treatment, but many more potential targets might have been previously overlooked. In this review, we will discuss the current state of small molecules that target various elements of ubiquitination. Special attention will be given to novel inhibitors of E3 ubiquitin ligases, especially those in the SCF family.

Entities:  

Keywords:  E3 ligase inhibition; SCF complex; Skp2 inhibitors; cancer therapeutics; deubiquitinase; high-throughput virtual screening; hot spots; in silico modeling; small molecule inhibitors; ubiquitination

Mesh:

Substances:

Year:  2015        PMID: 26630263      PMCID: PMC4976843          DOI: 10.4155/fmc.15.148

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  145 in total

1.  Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.

Authors:  S Fang; J P Jensen; R L Ludwig; K H Vousden; A M Weissman
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

Review 2.  Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.

Authors:  Martha Q Lacy; S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2010-02       Impact factor: 10.047

3.  Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.

Authors:  Luke F Peterson; Hanshi Sun; Yihong Liu; Harish Potu; Malathi Kandarpa; Monika Ermann; Stephen M Courtney; Matthew Young; Hollis D Showalter; Duxin Sun; Andrzej Jakubowiak; Sami N Malek; Moshe Talpaz; Nicholas J Donato
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

4.  Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis.

Authors:  Szu-Wei Lee; Chien-Feng Li; Chia-Hsin Chan; Jing Wang; Wei-Lei Yang; Ching-Yuan Wu; Juan Wu; Keiichi I Nakayama; Hong-Yo Kang; Hsuan-Ying Huang; Mien-Chie Hung; Pier Paolo Pandolfi; Hui-Kuan Lin
Journal:  Nat Cell Biol       Date:  2010-04-11       Impact factor: 28.824

Review 5.  Ubiquitin: roles in protein modification and breakdown.

Authors:  A Hershko
Journal:  Cell       Date:  1983-08       Impact factor: 41.582

6.  Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.

Authors:  Thomas Leonard Joseph; Arumugam Madhumalar; Christopher J Brown; David P Lane; Chandra S Verma
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

7.  Structure of a ubiquitin-loaded HECT ligase reveals the molecular basis for catalytic priming.

Authors:  Elena Maspero; Eleonora Valentini; Sara Mari; Valentina Cecatiello; Paolo Soffientini; Sebastiano Pasqualato; Simona Polo
Journal:  Nat Struct Mol Biol       Date:  2013-05-05       Impact factor: 15.369

Review 8.  MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Authors:  Steffan T Nawrocki; Patrick Griffin; Kevin R Kelly; Jennifer S Carew
Journal:  Expert Opin Investig Drugs       Date:  2012-07-16       Impact factor: 6.206

9.  Enhancement of proteasome activity by a small-molecule inhibitor of USP14.

Authors:  Byung-Hoon Lee; Min Jae Lee; Soyeon Park; Dong-Chan Oh; Suzanne Elsasser; Ping-Chung Chen; Carlos Gartner; Nevena Dimova; John Hanna; Steven P Gygi; Scott M Wilson; Randall W King; Daniel Finley
Journal:  Nature       Date:  2010-09-09       Impact factor: 49.962

Review 10.  Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.

Authors:  Christina Lutz-Nicoladoni; Dominik Wolf; Sieghart Sopper
Journal:  Front Oncol       Date:  2015-03-11       Impact factor: 6.244

View more
  33 in total

Review 1.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

2.  Cell division cycle 34 is highly expressed in hepatitis C virus-positive hepatocellular carcinoma with favorable phenotypes.

Authors:  Keiko Takagi; Tadatoshi Takayama; Yutaka Midorikawa; Hiromasa Hasegawa; Takanaga Ochiai; Masamichi Moriguchi; Tokio Higaki; Masayoshi Soma; Hiroki Nagase; Kyoko Fujiwara
Journal:  Biomed Rep       Date:  2017-05-18

Review 3.  Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.

Authors:  Murali Munisamy; Nayonika Mukherjee; Levin Thomas; Amy Trinh Pham; Arash Shakeri; Yusheng Zhao; Jill Kolesar; Praveen P N Rao; Vivek M Rangnekar; Mahadev Rao
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

4.  Highly Multiplexed Quantitative Mass Spectrometry Analysis of Ubiquitylomes.

Authors:  Christopher M Rose; Marta Isasa; Alban Ordureau; Miguel A Prado; Sean A Beausoleil; Mark P Jedrychowski; Daniel J Finley; J Wade Harper; Steven P Gygi
Journal:  Cell Syst       Date:  2016-09-22       Impact factor: 10.304

5.  Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens.

Authors:  Karla D Passalacqua; Marie-Eve Charbonneau; Nicholas J Donato; Hollis D Showalter; Duxin Sun; Bo Wen; Miao He; Hanshi Sun; Mary X D O'Riordan; Christiane E Wobus
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

6.  UCHL3 promotes proliferation of colorectal cancer cells by regulating SOX12 via AKT/mTOR signaling pathway.

Authors:  Jiangning Li; Yang Zheng; Xiaofeng Li; Xue Dong; Weiyan Chen; Zhongying Guan; Chong Zhang
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 7.  Fine-tuning the ubiquitin-proteasome system to treat pulmonary fibrosis.

Authors:  Willy Roque; Ross Summer; Freddy Romero
Journal:  Connect Tissue Res       Date:  2018-10-22       Impact factor: 3.417

8.  Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta.

Authors:  Mengmeng Zhao; Asuka Nanbo; David Becnel; Zhiqiang Qin; Gilbert F Morris; Li Li; Zhen Lin
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

Review 9.  Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity.

Authors:  Utsa Bhaduri; Giuseppe Merla
Journal:  Cells       Date:  2021-04-25       Impact factor: 6.600

10.  MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2.

Authors:  Jie Sun; Zheng Dong; Zhengyao Chang; Hongfei Liu; Qiyu Jiang; Deyuan Zhang; Shanshan Lu; Xiaodong Jia; Dawei Wu; Aaron Ge; Pan Zhao; Jing Wang; Yinying Lu
Journal:  BMC Cancer       Date:  2021-07-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.